Biological
Advexin clinical trials
Also written INGN-201, ADVEXIN and Ad5CMV-p53.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 1998 (6)
| Year | Studies |
|---|---|
| 1998 | 6 |
| 1999 | 1 |
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 9
National Cancer Institute (NCI) (4) · Eastern Cooperative Oncology Group (2) · University of Texas Southwestern Medical Center (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · Introgen Therapeutics (1) · SWOG Cancer Research Network (1) · MultiVir, Inc. (1) · Aventis Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses advexin is read from its arms, and is right about nine times in ten.
Testing it · 12
- Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically RemovedCompletedPhase 1Eastern Cooperative Oncology GroupNCT00003649Written as Ad5CMV-p53 gene
- Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal CancerCompletedPhase 1University of Texas Southwestern Medical CenterNCT00003450Written as Ad5CMV-p53 gene
- Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.Status unknownPhase 2MultiVir, Inc.NCT03544723Written as Ad-p53
- Gene Therapy in Treating Patients With Recurrent Malignant GliomasCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00004041Written as Ad5CMV-p53 gene
- Gene Therapy in Treating Patients With Recurrent Head and Neck CancerStatus unknownPhase 2Aventis PharmaceuticalsNCT00003257Written as Ad5CMV-p53 gene
- Chemotherapy Combined With Gene Therapy in Treating Patients Who Have Stage III or Stage IV Breast CancerCompletedPhase 2Introgen TherapeuticsNCT00044993Written as Ad5CMV-p53 gene
- Gene Therapy in Treating Patients With Ovarian CancerCompletedPhase 1National Cancer Institute (NCI)NCT00003588Written as Ad5CMV-p53 gene
- Gene Therapy in Treating Patients With Cancer of The LiverTerminatedPhase 1National Cancer Institute (NCI)NCT00003147Written as Ad5CMV-p53 gene
- Gene Therapy in Treating Patients With Advanced Bladder CancerCompletedPhase 1National Cancer Institute (NCI)NCT00003167Written as Ad5CMV-p53 gene
- Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or PharynxCompletedPhase 1/2National Cancer Institute (NCI)NCT00064103Written as Ad5CMV-p53 gene
- S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or ThroatTerminatedPhase 2SWOG Cancer Research NetworkNCT00017173Written as Ad5CMV-p53 gene
- Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung CancerCompletedPhase 1Eastern Cooperative Oncology GroupNCT00004225Written as Ad5CMV-p53 gene
Given in every arm · 2 — advexin is usual care beside what is tested
- Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell CancerTerminatedPhase 1/2MultiVir, Inc.NCT02842125Written as Ad-P53
- Gene Therapy Plus Chemotherapy in Treating Patients With Breast CancerCompletedPhase 1National Cancer Institute (NCI)NCT00004038Written as Ad5CMV-p53 gene